Skip Nav Destination
Issues
1 March 2011
-
Cover Image
Cover Image
EGFR-overexpressing A431 cells were transfected with PolyIC/MPPE at 0.1 mcg/mL, 24 hours later, 500,000 PBMCs per well were added to the cancer cells and coincubated for another 24 hours. Apoptotic cells (red fluorescence) were visualized using an Annexin-V-Biotin kit. To distinguish tumor cells from PBMCs, tumor cells were labeled with FITC-conjugated EGFR antibody (green fluorescence). Cells were visualized with a fluorescent microscope and photographed using a digital camera. For further details, please see Shir and coworkers on page 1033 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Cancer Therapy: Preclinical
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin; Maureen R. Bleam; Arthur Groy; Katherine G. Moss; Elisabeth A. Minthorn; Swarupa G. Kulkarni; Cynthia M. Rominger; Symon Erskine; Kelly E. Fisher; Jingsong Yang; Francesca Zappacosta; Roland Annan; David Sutton; Sylvie G. Laquerre
Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth
Hanhua Huang; Jing-Yu Lai; Janet Do; Dingguo Liu; Lingna Li; Joselyn Del Rosario; Venkata R. Doppalapudi; Steven Pirie-Shepherd; Nancy Levin; Curt Bradshaw; Gary Woodnutt; Rodney Lappe; Abhijit Bhat
FKBPL and Peptide Derivatives: Novel Biological Agents That Inhibit Angiogenesis by a CD44-Dependent Mechanism
Andrea Valentine; Martin O'Rourke; Anita Yakkundi; Jenny Worthington; Michelle Hookham; Roy Bicknell; Helen O. McCarthy; Keeva McClelland; Lynn McCallum; Hayder Dyer; Hayley McKeen; David J. J. Waugh; Jennifer Roberts; Joanne McGregor; Graham Cotton; Iain James; Timothy Harrison; David G. Hirst; Tracy Robson
Imaging, Diagnosis, Prognosis
Prostate Cancer Predisposition Loci and Risk of Metastatic Disease and Prostate Cancer Recurrence
Jiyoung Ahn; Adam S. Kibel; Jong Y. Park; Timothy R. Rebbeck; Hanna Rennert; Janet L. Stanford; Elaine A. Ostrander; Stephen Chanock; Ming-Hsi Wang; Rama D. Mittal; William B. Isaacs; Elizabeth A. Platz; Richard B. Hayes
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo; Kirsten M. Timms; Shuying Liu; Huiqin Chen; Jennifer K. Litton; Jennifer Potter; Jerry S. Lanchbury; Katherine Stemke-Hale; Bryan T. Hennessy; Banu K. Arun; Gabriel N. Hortobagyi; Kim-Anh Do; Gordon B. Mills; Funda Meric-Bernstam
Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer
Richard Morgan; Angela Boxall; Aagna Bhatt; Michael Bailey; Richard Hindley; Stephen Langley; Hayley C. Whitaker; David E. Neal; Mohammed Ismail; Hamish Whitaker; Nicola Annels; Agnieszka Michael; Hardev Pandha
Imaging Colon Cancer Response Following Treatment with AZD1152: A Preclinical Analysis of [18F]Fluoro-2-deoxyglucose and 3′-deoxy-3′-[18F]Fluorothymidine Imaging
Maxim A. Moroz; Tatiana Kochetkov; Shangde Cai; Jiyuan Wu; Mikhail Shamis; Jayasree Nair; Elisa de Stanchina; Inna Serganova; Gary K. Schwartz; Debabrata Banerjee; Joseph R. Bertino; Ronald G. Blasberg
KPNA2 Expression Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy
Ashkan Mortezavi; Thomas Hermanns; Hans-Helge Seifert; Martin K. Baumgartner; Maurizio Provenzano; Tullio Sulser; Maximilian Burger; Matteo Montani; Kristian Ikenberg; Ferdinand Hofstädter; Arndt Hartmann; Rolf Jaggi; Holger Moch; Glen Kristiansen; Peter J. Wild
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
Jeanne Tie; Lara Lipton; Jayesh Desai; Peter Gibbs; Robert N. Jorissen; Michael Christie; Katharine J. Drummond; Benjamin N.J. Thomson; Valery Usatoff; Peter M. Evans; Adrian W. Pick; Simon Knight; Peter W.G. Carne; Roger Berry; Adrian Polglase; Paul McMurrick; Qi Zhao; Dana Busam; Robert L. Strausberg; Enric Domingo; Ian P.M. Tomlinson; Rachel Midgley; David Kerr; Oliver M. Sieber
Cancer Therapy: Clinical
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Pasi A. Jänne; David S. Boss; D. Ross Camidge; Carolyn D. Britten; Jeffrey A. Engelman; Edward B. Garon; Feng Guo; Steven Wong; Jane Liang; Stephen Letrent; Robert Millham; Ian Taylor; S. Gail Eckhardt; Jan H.M. Schellens
A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias
Jeffrey E. Lancet; Vu H. Duong; Elliott F. Winton; Robert K. Stuart; Michelle Burton; Shumin Zhang; Christopher Cubitt; Michelle A. Blaskovich; John J. Wright; Said Sebti; Daniel M. Sullivan
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
C. Kent Osborne; Patrick Neven; Luc Y. Dirix; John R. Mackey; Jean Robert; Craig Underhill; Rachel Schiff; Carolina Gutierrez; Ilenia Migliaccio; Valsamo K. Anagnostou; David L. Rimm; Patrick Magill; Mark Sellers
Predictive Biomarkers and Personalized Medicine
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Rafael Rosell; Miguel Angel Molina; Carlota Costa; Sara Simonetti; Ana Gimenez-Capitan; Jordi Bertran-Alamillo; Clara Mayo; Teresa Moran; Pedro Mendez; Felipe Cardenal; Dolores Isla; Mariano Provencio; Manuel Cobo; Amelia Insa; Rosario Garcia-Campelo; Noemi Reguart; Margarita Majem; Santiago Viteri; Enric Carcereny; Ruth Porta; Bartomeu Massuti; Cristina Queralt; Itziar de Aguirre; Jose Miguel Sanchez; Maria Sanchez-Ronco; Jose Luis Mate; Aurelio Ariza; Susana Benlloch; Jose Javier Sanchez; Trever G Bivona; Charles L Sawyers; Miquel Taron
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Maria E. Arcila; Geoffrey R. Oxnard; Khedoudja Nafa; Gregory J. Riely; Stephen B. Solomon; Maureen F. Zakowski; Mark G. Kris; William Pao; Vincent A. Miller; Marc Ladanyi
Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
Ronan J. Kelly; Arun Rajan; Jeremy Force; Ariel Lopez-Chavez; Corrine Keen; Liang Cao; Yunkai Yu; Peter Choyke; Baris Turkbey; Mark Raffeld; Liqiang Xi; Seth M. Steinberg; John J. Wright; Shivaani Kummar; Martin Gutierrez; Giuseppe Giaccone
Correction
Advertisement